Is fda approval a priority listing in the United States?

Fda approves priority listing in the United States.

The FDA's approval of new drugs is mainly based on the chemical types and therapeutic potential of drugs.

Introduction to FDA:

According to chemical types, new drugs are mainly divided into:

1 class: a new molecular compound (NME). It has never been approved as a drug in America.

Or an active ingredient sold, which can be a single ingredient or a part of a stereoisomeric mixture;

The second category: new derivatives. Derived from active ingredients that have been listed (so-called "patented" drugs), that is, they have been listed in the United States.

Esters, salts or other non-valence bond derivatives of listed active ingredients, or parent compounds with modified groups are not allowed to be listed in the United States;

The third category: new preparations. New dosage forms or prescriptions containing active ingredients on the market,

Indications can be the same as or different from products on the market;

The fourth category: new combinations. There are two or more kinds of active ingredients in the market, but there is no such combination in the listed products;

The fifth category: imitation, imitation of other factories.

Products already on the market have the same active ingredients, formulas or combinations;

Category 6: New indications. Replicas with new uses approved or listed by the same company or other companies in the United States;

Category 7: Listed but not approved.

Drugs approved by NDA. Indications are the same as those of listed products, or they may be different;

Category 8: over-the-counter drugs;

Category 9: Application for new drugs with different indications.